secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2021-10-21T23:59:59+00:00
Accession:  0001193125-21-304002
Event type: leadership
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Leen Kawas resigns after special committee finds she altered images in doctoral research; Mark Litton appointed CEO.
--------------------------------------------------------------------------------

- Special committee concluded Dr. Kawas altered images in her 2011 dissertation and at least four research papers co-authored as a WSU graduate student.
- Mark Litton, Ph.D., MBA, appointed President and CEO and to the board; Rachel Lenington, MBA, appointed COO, effective Oct 18, 2021.
- Severance: Kawas receives lump sum of $510,000 plus COBRA reimbursement for up to 18 months; retains options for 363,535 shares.
- ATH-1017 patent does not cite altered-image papers; Phase 1a/b trial results reaffirmed as statistically significant per independent audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312521304002/0001193125-21-304002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312521304002/d179221d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-304002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer